Ophthalmologist

deepeye® tps

1-click Predictive AI Assistant for Personalised Treatment

Empowering Your Practice

With deepeye, embark on a journey towards significantly enhanced treatment outcomes. Experience a seamless workflow, enriched with precise analysis of 3D retinal scans (OCTs), enabling more informed decisions in retinal therapy, particularly through intravitreal injections (IVI) utilizing anti-VEGF inhibitors. Your path towards optimized patient care begins here.

See our product

Compatibility with 90% of existing OCT imaging software

Proven clinical benefits of expert 2nd opinions with
a validated AI

Patients

UP TO

3X

higher vision gains
&
lower treatment burden

Eye Doctors

UP TO

2X

more patients &
additional reimbursement
per therapy

Healthcare System

Estimated

€15K

savings per patient
remaining in therapy
(2.5x savings)

Benefiting Your Patients

deepeye isn't just a tool, it's a commitment towards improving the lives of individuals afflicted with retinal diseases. With our AI-driven prognostics, prepare your patients for a better tomorrow, armed with a proactive treatment plan, reducing the treatment burden and fostering a future with clearer vision.

Request a Demo

Clinical Outcome Enhancement

More than just data, deepeye delivers actionable insights, aiding in robust treatment planning that overcome the limitations of conventional treatment regimen like T&E, PRN, IVAN, and CATT. Our pursuit of algorithmic refinement aims to redefine the treatment narrative for retinal diseases towards a (patient) need-based "predict & treat" (P&T).

Read related publications

Source: L.Spickermann et al.: “Analyse des Versorgungsmodells „Portal“ – 4-Jahres Untersuchung der Ergebnisqualität der IVOM- Therapie in Hinblick auf Latenzzeiten bei exsudativer AMD”, DOG Congress 2024, Berlin. Presentation Fr20f-04

Based on Leading
Clinicians Literature

Human expert 2nd opinions are a proven clinical method (Münster IVI Portal), that demonstrated:
‍
3X Higher Visual Acuity compared to average outcomes after 24 months in therapy
‍
2X more patients remaining in therapy after 24 months

More infos about this methodology

Reach out to our Regulatory Affairs Team

We value your feedback and understand that you may have questions or concerns regarding our medical device software products (not yet available for clinical use). Our Regulatory Affairs team is here to assist you. Whether you have a product complaint, a suggestion, or just need more information, we are happy to help. Your input is important to us and helps us continually improve our products and services.

Let's talk